RNS Number : 9979F
  Lipoxen PLC
  17 October 2008
   

    Lipoxen PLC
    ("Lipoxen" or "the Company")

    Additional listing

    London, UK, 17 October 2008 - Lipoxen PLC (AIM:LPX) a bio-pharmaceutical company specialising in the development of high value
differentiated biologicals, vaccines and oncology drugs, announces that application has been made to AIM, a market of the London Stock
Exchange plc, for the admission of 135,658 ordinary shares of 0.5p each (the "New Ordinary Shares").

    The New Ordinary Shares are being admitted pursuant to the exercise of options under the Lipoxen Plc Unapproved Share Option Plan.

    It is expected that dealing in the New Ordinary Shares, which will rank pari passu in all respects with the existing issued share
capital of the Company, will commence on 21 October 2008.

    Enquiries 

 Lipoxen PLC
 M. Scott Maguire, Chief Executive Officer  +44 (0)20 7691 3583 
 Colin Hill, Finance Director

 Teathers Ltd (nominated adviser)
 Shaun Dobson / Claes Spg                   +44 (0)20 7426 9000

 Citigate Dewe Rogerson                     +44 (0)20 7638 9571
  
 David Dible / Heather Keohane



This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
LISEAEEKFDAPFFE
Lipoxen (LSE:LPX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Lipoxen Charts.
Lipoxen (LSE:LPX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Lipoxen Charts.